Catalyst Wire Dossier Catalyst Wire Dossier

HRS-9821 powder for inhalation

· Guangdong Hengrui Pharmaceutical Co., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HRS-9821 powder for inhalation, covering 2026-02-27 to 2026-02-27. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD. [Phase 1]

See pricing